

Appendix 2: Details of additional consortium members, acknowledgements, and funding [posted as supplied by author]

The PRACTICAL CONSORTIUM

Information about the consortium and/or how to access the data used in this model can be found at <http://practical.ccge.medschl.cam.ac.uk/>

Members of the consortium (in addition to those named in the author list):

Margaret Cook¹
Michelle Guy²
Koveela Govindasami²
Daniel Leongamornlert²
Emma J. Sawyer²
Rosemary Wilkinson²
Edward J. Saunders²
Malgorzata Tymrakiewicz²
Tokhir Dadaev²
Angela Morgan²
Cyril Fisher²
Steve Hazel²
Naomi Livni²
Artitaya Lophatananon^{3,4}
Robert Szulkin⁵
Jan Adolfsson^{6,7}
Pär Stattin^{8,9}
Jan-Erik Johansson^{5,10}
Carin Cavalli-Bjoerkman⁵
Ami Karlsson⁵
Michael Broms⁵
Anssi Auvinen¹¹
Paula Kujala¹²
Kirsi Talala¹³
Teemu Murtola^{14,15}
Kimmo Taari¹⁶
Peter Klarskov¹⁷
Hans Wallinder¹⁸
Sven Gustafsson¹⁸
Angela Cox¹⁹
Paul Brown²⁰
Anne George²⁰
Gemma Marsden²⁰
Athene Lane²⁰
Michael Davis²⁰
Wei Zheng²¹
Lisa B. Signorello²²
William J. Blot^{23,24}
Lori Tillmans²⁵
Shaun Riska²⁵
Liang Wang²⁵
Antje Rincklebe²⁶
Jan Lubinski²⁷
Christa Stegmaier²⁸
Julio Pow-Sang²⁹
Hyun Park²⁹
Selina Radlein²⁹
Maria Rincon²⁹
James Haley²⁹
Babu Zachariah²⁹

Darina Kachakova³⁰
Elenko Popov³¹
Atanaska Mitkova³⁰
Aleksandrina Vlahova³²
Tihomir Dikov³²
Svetlana Christova³²
Peter Heathcote³³
Glen Wood³³
Greg Malone³³
Pamela Saunders³³
Allison Eckert³³
Trina Yeadon³³
Kris Kerr³³
Angus Collins³³
Megan Turner³³
Srilakshmi Srinivasan³³
Mary-Anne Kedda³³
Kimberly Alexander³³
Tracy Omara³³
Huihai Wu³⁴
Rui Henrique³⁵
Pedro Pinto³⁵
Joana Santos³⁵
Joao Barros-Silva³⁵
Mohamed El Tibi³⁶
Graham G. Giles^{37,38}
Melissa C. Southey³⁹
Liesel M. Fitzgerald⁴⁰
John Pedersen⁴¹
John L. Hopper⁴²
Robert MacInnis^{37,42}
Brian E. Henderson⁴³
Fredrick Schumacher⁴⁴
Christopher A. Haiman⁴³
Janet L. Stanford^{45,46}
Susanne Kolb⁴⁵
Yong-Jie Lu⁴⁷
Hong-Wei Zhang⁴⁸

¹Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, UK

²The Institute of Cancer Research, London, SM2 5NG, UK

³Institute of Population Health, University of Manchester, Manchester, UK

⁴Warwick Medical School, University of Warwick, Coventry, UK

⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

⁶Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden

⁷Swedish Agency for Health Technology Assessment and Assessment of Social Services, Stockholm, Sweden

⁸Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden

⁹Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

¹⁰Department of Urology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

¹¹Department of Epidemiology, School of Health Sciences, University of Tampere, Tampere, Finland

¹²Fimlab Laboratories, Tampere University Hospital, Tampere, Finland

¹³Finnish Cancer Registry, Helsinki, Finland

¹⁴School of Medicine, University of Tampere, Tampere, Finland

¹⁵Department of Urology, Tampere University Hospital, Tampere, Finland

¹⁶Department of Urology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland

¹⁷Department of Urology, Herlev Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-230 Herlev, Denmark.

¹⁸Department of Epidemiology and Biostatistics, School of Public Health, Imperial College, London, United Kingdom

- ¹⁹CR-UK/YCR Sheffield Cancer Research Centre, University of Sheffield, Sheffield, UK
- ²⁰School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK
- ²¹Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 800, Nashville, TN 37232 USA.
- ²²National Cancer Institute, NIH, 9609 Medical Center Drive, Suite 2W-172, MSC 9712, Bethesda, MD, 20892-9712 (mail), Rockville, MD 20850 (FedEx/Courier), USA
- ²³International Epidemiology Institute, 1555 Research Blvd., Suite 550, Rockville, MD 20850, USA
- ²⁴Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, US
- ²⁵Mayo Clinic, Rochester, Minnesota, USA
- ²⁶Department of Urology, University Hospital Ulm, Germany
- ²⁷International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
- ²⁸Saarland Cancer Registry, 66119 Saarbrücken, Germany
- ²⁹Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
- ³⁰Department of Medical Chemistry and Biochemistry, Molecular Medicine Center, Medical University, Sofia, 2 Zdrave Str., 1431 Sofia, Bulgaria
- ³¹Department of Urology and Alexandrovska University Hospital, Medical University, Sofia, Bulgaria
- ³²Department of General and Clinical Pathology
- ³³Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Science, Queensland University of Technology, Brisbane, Australia
- ³⁴The University of Surrey, Guildford, Surrey, GU2 7XH
- ³⁵Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
- ³⁶University Hospital "Tsaritsa Yoanna", Medical University - Sofia, Sofia, †Bulgaria
- ³⁷Cancer Epidemiology Centre, Cancer Council Victoria, 615 St Kilda Road, Melbourne, Victoria, 3004, Australia
- ³⁸Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria 3010, Australia
- ³⁹Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia
- ⁴⁰Cancer Epidemiology Centre, Cancer Council Victoria, 615 St Kilda Road, Melbourne, Victoria, Australia
- ⁴¹Tissupath Pty Ltd., Melbourne, Victoria 3122, Australia
- ⁴²Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia
- ⁴³Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California, US
- ⁴⁴Case Western Reserve University, School of Medicine, 10900 Euclid Ave., Cleveland, OH, 44106-4945, USA
- ⁴⁵Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, USA
- ⁴⁶Department of Epidemiology, School of Public Health, University of Washington, Seattle, Washington, US
- ⁴⁷Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK
- ⁴⁸Second Military Medical University, 800 Xiangyin Rd., Shanghai 200433, P. R. China

Funding for the CRUK study and PRACTICAL consortium:

This work was supported by the Canadian Institutes of Health Research, European Commission's Seventh Framework Programme grant agreement n° 223175 (HEALTH-F2-2009-223175), Cancer Research UK Grants C5047/A7357, C1287/A10118, C5047/A3354, C5047/A10692, C16913/A6135, and The National Institute of Health (NIH) Cancer Post-Cancer GWAS initiative grant: No. 1 U19 CA 148537-01 (the GAME-ON initiative).

COGS acknowledgement:

This study would not have been possible without the contributions of the following: Per Hall (COGS); Douglas F. Easton, Paul Pharoah, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang (BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Douglas F. Easton, Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken Offit (CIMBA), Joe Dennis, Alison M. Dunning, Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the

Centre for Genetic Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility

Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.

Additional funding and acknowledgments from studies in PRACTICAL:

The Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden was supported by the Cancer Risk Prediction Center (CRiSP; www.crispcenter.org), a Linneus Centre (Contract ID 70867902) financed by the Swedish Research Council, Swedish Research Council (grant no K2010-70X-20430-04-3), the Swedish Cancer Foundation (grant no 09-0677), the Hedlund Foundation, the Soederberg Foundation, the Enqvist Foundation, ALF funds from the Stockholm County Council. Stiftelsen Johanna Hagstrand och Sigfrid Linner's Minne, Karlsson's Fund for urological and surgical research. We thank and acknowledge all of the participants in the Stockholm-1 study. We thank Carin Cavalli-Bjoerkman and Ami Roennberg Karlsson for their dedicated work in the collection of data. Michael Broms is acknowledged for his skilful work with the databases. KI Biobank is acknowledged for handling the samples and for DNA extraction. Hans Wallinder at Aleris Medilab and Sven Gustafsson at Karolinska University Laboratory are thanked for their good cooperation in providing historical laboratory results.

The coordination of EPIC was financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts (that recruited male participants) are supported by Danish Cancer Society (Denmark); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS), PI13/00061 to Granada; , PI13/01162 to EPIC-Murcia), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, ISCIII RETIC (RD06/0020) (Spain); Swedish Cancer Society, Swedish Research Council and County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 and C8221/A19170 to EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (United Kingdom). For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at <http://epic.iarc.fr/access/index.php>.

The ESTHER study was supported by a grant from the Baden Württemberg Ministry of Science, Research and Arts. Additional cases were recruited in the context of the VERDI study, which was supported by a grant from the German Cancer Aid (Deutsche Krebshilfe). The ESTHER group would like to thank Hartwig Ziegler, Sonja Wolf, Volker Hermann, Katja Butterbach.

The FHCRC studies were supported by grants RO1CA056678, RO1CA082664, and RO1CA092579 from the US National Cancer Institute, National Institutes of Health, with additional support from the Fred Hutchinson Cancer Research Center.

The IPO-Porto study was in part funded by Liga Portuguesa Contra o Cancro.

The Mayo group was supported by the US National Cancer Institute (R01CA72818)

The Prostate Cancer Program of Cancer Council Victoria also acknowledge grant support from The National Health and Medical Research Council, Australia (126402, 209057, 251533, , 396414, 450104, 504700, 504702, 504715, 623204, 940394, 614296,), VicHealth, Cancer Council Victoria, The Prostate Cancer Foundation of Australia, The Whitten Foundation, PricewaterhouseCoopers, and Tattersall's. EAO, DMK, and EMK acknowledge the Intramural Program of the National Human Genome Research Institute for their support.

The MEC was supported by NIH grants CA63464, CA54281 and CA098758.

The Moffitt group was supported by the US National Cancer Institute (R01CA128813, PI: J.Y. Park).

The PCMUS study was supported by the Bulgarian National Science Fund, Ministry of Education and Science (contract DOO-119/2009; DUNK01/2-2009; DFNI-B01/28/2012) with additional support from the Science Fund of Medical University - Sofia (contract 51/2009; 81/2009; 28/2010).

ProtecT would like to acknowledge the support of The University of Cambridge, Cancer Research UK. Cancer Research UK grants [C8197/A10123] and [C8197/A10865] supported the genotyping team. We would also like to acknowledge the support of the National Institute for Health Research which funds the Cambridge Biomedical Research Centre, Cambridge, UK. We would also like to acknowledge the support of the National Cancer Research Prostate Cancer: Mechanisms of Progression and Treatment (PROMPT) collaborative (grant code G0500966/75466) which has funded tissue and urine collections in Cambridge. We are grateful to staff at the Wellcome Trust Clinical Research Facility, Addenbrooke's Clinical Research Centre, Cambridge, UK for their help in conducting the ProtecT study. We also acknowledge the support of the NIHR Cambridge Biomedical Research Centre, the DOH HTA (ProtecT grant) and the NCRI / MRC (ProMPT grant) for help with the bio-repository. The UK Department of Health funded the ProtecT study through the NIHR Health Technology Assessment Programme (projects 96/20/06, 96/20/99). The ProtecT trial and its linked ProMPT and CAP (Comparison Arm for ProtecT) studies are supported by Department of Health, England; Cancer Research UK grant number C522/A8649, Medical Research Council of England grant number G0500966, ID 75466 and The NCRI, UK. The epidemiological data for ProtecT were generated through funding from the Southwest National Health Service Research and Development. DNA extraction in ProtecT was supported by USA Dept of Defense award W81XWH-04-1-0280, Yorkshire Cancer Research and Cancer Research UK. The authors would like to acknowledge the contribution of all members of the ProtecT study research group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health of England. The bio-repository from ProtecT is supported by the NCRI (ProMPT) Prostate Cancer Collaborative and the Cambridge BMRC grant from NIHR.

The QLD research is supported by The National Health and Medical Research Council, Australia Project Grant [390130, 1009458] and Enabling Grant [614296 to APCB]; the Prostate Cancer Foundation of Australia (Project Grant [PG7] and Research Grant [to APCB]).

SCCS is funded by NIH grant R01 CA092447, and SCCS sample preparation was conducted at the Epidemiology Biospecimen Core Lab that is supported in part by the Vanderbilt-Ingram Cancer Center (P30 CA68485). Data on SCCS cancer cases used in this publication were provided by the Alabama Statewide Cancer Registry; Kentucky Cancer Registry, Lexington, KY; Tennessee Department of Health, Office of Cancer Surveillance; Florida Cancer Data System; North Carolina Central Cancer Registry, North Carolina Division of Public Health; Georgia Comprehensive Cancer Registry; Louisiana Tumor Registry; Mississippi Cancer Registry; South Carolina Central Cancer Registry; Virginia Department of Health, Virginia Cancer Registry; Arkansas Department of Health, Cancer Registry, 4815 W. Markham, Little Rock, AR 72205. The Arkansas Central Cancer Registry is fully funded by a grant from National Program of Cancer Registries, Centers for Disease Control and Prevention (CDC). Data on SCCS cancer cases from Mississippi were collected by the Mississippi Cancer Registry which participates in the National Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi Cancer Registry. SEARCH is funded by a programme grant from Cancer Research UK [C490/A10124] and supported by the UK National Institute for Health Research Biomedical Research Centre at the University of Cambridge.

The Tampere (Finland) study was supported by the Academy of Finland (251074), The Finnish Cancer Organisations, Sigrid Juselius Foundation, and the Competitive Research Funding of the Tampere University Hospital (9N069 and X51003). The PSA screening samples were collected by the Finnish part of ERSPC (European Study of Screening for Prostate Cancer). Riina Liikanen is thanked for technical assistance. Riitta Vaalavuori and Liisa Maeaettaenen are thanked for their work with databases.

UKGPCS would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK (now Prostate Action), The Orchid Cancer Appeal, The National Cancer Research Network UK, The National Cancer Research Institute (NCRI) UK. We are grateful for support of NIHR funding to the NIHR Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. UKGPCS should also like to acknowledge the NCRN nurses, data managers and Consultants for their work in the UKGPCS study. UKGPCS would like to thank all urologists and other persons involved in the planning, coordination, and data collection of the CAPS study.

The Ulm group received funds from the German Cancer Aid (Deutsche Krebshilfe).

The Keith and Susan Warshaw Fund, C. S. Watkins Urologic Cancer Fund and The Tenny Family Fund supported the Utah study. The project was supported by Award Number P30CA042014 from the National Cancer Institute